Metsera (MTSR) Study Result summary

Study design and objectives

• Phase 1 trial of MET-233/MET-233i included single and multiple ascending dose cohorts in overweight or obese adults without type 2 diabetes, with 40 participants in each part and a total of 80 participants.

• Dosing ranged from 0.15 to 2.4 mg in SAD and 0.15 to 1.2 mg in MAD, with balanced demographics and a mean BMI of approximately 32.

• The study used a randomized, placebo-controlled, double-blind design.

• Primary objectives were to characterize pharmacokinetics, measure weight loss at one and five weeks, and identify well-tolerated starting doses.

Pharmacokinetics and dosing

• MET-233/MET-233i demonstrated a 19-day observed half-life, supporting once-monthly dosing.

• Dose-linear pharmacokinetics with low variability and matched exposure profiles with MET-097i support combinability.

Efficacy results

• Up to 8.4% placebo-subtracted mean weight loss was observed after five weekly doses in the MAD cohort, with individual responses as high as 10.2%.

• Dose-dependent and rapid onset of weight loss was observed, with efficacy at low, scalable peptide doses.